Why a Stem Cell CEO Just Ditched His Own Field for Nuclear Medicine

In other words, this isn't some mid-career pivot driven by curiosity. It's a calculated bet by someone who's been watching the radiopharmaceutical space heat up and decided he wanted to drive.

What Orano Med Is Actually Building

Orano Med's lead program is AlphaMedix, a lead-212-based therapy targeting gastroenteropancreatic neuroendocrine tumors (GEP-NETs, a type of cancer that forms in the digestive system). The Phase 2 trial hit all of its primary efficacy endpoints, working in both patients who'd never had radiation therapy before and those who had already been treated. The FDA granted it Breakthrough Therapy Designation in February 2024, which is the agency's way of saying "we think this could be important, let's speed things up."

Sanofi liked it enough to take an equity stake in Orano Med and sign an out-licensing deal for AlphaMedix. That's not a small vote of confidence.

Beyond the lead program, Orano Med has three Phase 1 studies running. One collaboration with Molecular Partners targets small cell lung cancer using a novel protein scaffold called a DARPin. Another partnership with Roche involves a two-step approach for CEA-positive cancers (including certain colorectal cancers), with a Phase 1 trial expected to start in the first half of 2026.

The company also opened what it calls the world's first industrial-scale facility dedicated to lead-212-based therapy production, located in Brownsburg, Indiana. Current capacity sits at 10,000 doses per year, with plans to scale to 100,000 by decade's end. They even picked a location near the second-largest FedEx hub, because when your product is radioactive and decaying, shipping speed matters.

The Bigger Picture: Why Everyone Wants In

Desdouits' move isn't happening in a vacuum. The targeted alpha therapy market is projected to hit $1.2 billion in 2026, growing at roughly 17% annually. For context, that pace outstrips most corners of oncology.

The excitement makes sense when you look at the science. Traditional radiation therapy (and even newer beta-emitting radiopharmaceuticals like lutetium-177) casts a wider net. Alpha particles travel only a few cell widths before stopping, which means they deliver devastating energy to tumors with minimal collateral damage. Think of it as the difference between a sniper rifle and a shotgun.

The FDA issued draft guidance for radiopharmaceuticals in August 2025, signaling that the regulatory framework is catching up to the science. And clinical trial activity is accelerating: roughly 28 Phase 1 and Phase 1/2 alpha therapy trials were running in 2025, with about half using actinium-225 (another popular alpha emitter).

What It Means for TreeFrog

TreeFrog didn't skip a beat. The company appointed Mark Rothera as its new CEO in December 2025. Rothera brings over 35 years of biopharma experience, including CEO stints at Viracta, Silence Therapeutics, and Orchard Therapeutics (which he took public). His track record centers on scaling companies from development through commercialization, which is exactly what TreeFrog needs as its Parkinson's program approaches the clinic.

The company also has a growing partnership with Vertex for Type 1 Diabetes and is expanding its U.S. presence. So this is less a story about TreeFrog losing its leader and more about radiopharmaceuticals pulling talent like a magnet.

The Takeaway

When experienced biotech executives start migrating toward a new modality, pay attention. It's one of the clearest signals the industry sends. Desdouits didn't need to take this job; he chose it. He chose lead-212 over stem cells, nuclear physics over regenerative medicine, a company backed by a nuclear energy conglomerate over a well-funded European startup.

That tells you something about where the smart money thinks oncology is heading. Radiopharmaceuticals aren't just a niche anymore. They're becoming the main stage, and the talent is following the spotlight.

The Pill That Could Kill the Obesity Needle

Eli Lilly just got FDA approval for Foundayo, the first small-molecule obesity pill that you can take anytime, anywhere, no needles required. With $1.7 billion in projected first-year sales and a price that undercuts injectables by 85%, the GLP-1 wars just went oral.